A global leader in influenza prevention recently announced a significant investment in a new Research and Development (R&D) facility located in Waltham, Mass.
Seqirus, a business of CSL Limited, confirmed on February 7, 2022, the new facility will support the company’s growing R&D portfolio, focusing on a self-amplifying messenger RNA (sa-mRNA) technology platform, the next generation of mRNA technology.
Self-Amplifying Messenger RNA Transforms Common Flu Shots
Self-Amplifying Messenger RNA Transforms Common Flu Shots
A global leader in influenza prevention recently announced a significant investment in a new Research and Development (R&D) facility located in Waltham, Mass.
Seqirus, a business of CSL Limited, confirmed on February 7, 2022, the new facility will support the company’s growing R&D portfolio, focusing on a self-amplifying messenger RNA (sa-mRNA) technology platform, the next generation of mRNA technology.
AACR Addresses Impact of COVID-19 on Cancer Care Continuum
Issues include increased burden of COVID-19 in patients with cancer, lessons from COVID-19 with potential to improve cancer care
Test-to-Stay Program Safe for Facilitating In-Person Learning
Per-person positivity rate was 2.9 percent; maximum of 497,150 days of in-person school saved with daily testing
~30 Percent of Seniors Have Sequelae After Acute SARS-CoV-2
Greatest excess risk seen for respiratory failure, fatigue, hypertension, memory difficulties compared with matched individuals without COVID-19
New York State Lifts Indoor Mask Mandate
Move is not mandatory: It remains optional for businesses, local governments, and counties to enforce